Engagement of the mast cell high-affinity receptor for immunoglobulin E (IgE) Allergen-induced activation of the high-affinity receptor for IgE (FcRI) in mast cells and basophils plays a pivotal role in the initiation of allergic and inflammatory reactions. As a result of receptor engagement, mast cells and basophils release a variety of inflammatory mediators, such as histamine, arachidonic acid metabolites, and cytokines (1, 2). The activation of protein tyrosine kinases (PTKs) is one of the early and critical signaling events following FcRI engagement (3). Since FcRI belongs to the family of multisubunit antigen receptors that do not possess intrinsic PTK activity in their structure (1), the recruitment and activation of non-receptor PTKs is crucial for FcRI-mediated signal transduction (4).
Allergen-induced activation of the high-affinity receptor for IgE (FcRI) in mast cells and basophils plays a pivotal role in the initiation of allergic and inflammatory reactions. As a result of receptor engagement, mast cells and basophils release a variety of inflammatory mediators, such as histamine, arachidonic acid metabolites, and cytokines (1, 2) . The activation of protein tyrosine kinases (PTKs) is one of the early and critical signaling events following FcRI engagement (3) . Since FcRI belongs to the family of multisubunit antigen receptors that do not possess intrinsic PTK activity in their structure (1) , the recruitment and activation of non-receptor PTKs is crucial for FcRI-mediated signal transduction (4) .
FcRI is a tetrameric receptor composed of an ␣ subunit, a ␤ subunit, and a homodimer of disulfide-linked ␥ subunits (5) . The cytoplasmic domains of ␤ and ␥ subunits contain sequences known as the immunoreceptor tyrosine-based activation motifs (ITAMs) (6, 7) . The phosphorylation of the tyrosines of the ITAM allows the interaction of ITAMcontaining receptors with signaling proteins that have phosphotyrosine-recognizing Src homology 2 (SH2) domains (8, 9) .
Syk kinase is activated in FcRI-mediated signaling in mast cells (10, 11) . Syk possesses two SH2 domains toward the amino terminus of the protein that mediate high-affinity interactions with the tyrosine-phosphorylated ITAM of the ␤ and ␥ subunits of FcRI (9, 12) . The association of Syk with the ITAM of the ␥ subunit induces the phosphorylation and activation of Syk (11) (12) (13) and stimulates subsequent signaling events, including activation of phospholipase C-␥1 (PLC-␥1) and protein kinase C (PKC). Thus it is possible that selective inhibitors of Syk or specific blockers of the association of Syk with ITAMs may prevent signaling by FcRI.
Here, we report that a synthetic acridone-related compound, ER-27319, inhibits mast cell responses by inhibiting the phosphorylation and activation of Syk in these cells.
Henry Metzger (National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD). Purified GST-fusion protein encoding the phosphorylation site of HS1, targeted by Syk kinase, was kindly provided by Ulrich Blank (Immuno-Allergie, Institut Pasteur, Paris). Baculovirus expressed recombinant PKC␦ was kindly provided by Peter M. Blumberg (National Cancer Institute, National Institutes of Health, Bethesda, MD). Phosphorylated ITAMs of the ␥ subunit of the FcRI, DGVpYTGLSTRNQETpYETLK, and the ␤ subunit of the B cell antigen receptor (Ig␤), DHTpYEGLNIDQTATpYEDIVT, were synthesized by the Peptide Institute (Osaka, Japan). ER-27319 [3,4-dimethyl-10(-3-aminopropyl)-9-acridone oxalate] and Ro31-8425 were synthesized in our laboratory. Enhanced chemiluminescence (ECL) system was from Amersham International (Buckinghamshire, England). Male Sprague-Dawley rats were purchased from Japan SLC (Hamamatsu, Japan).
Stock solutions of the pharmacological agents Ro31-8425, phorbol 12-myristate 13-acetate (PMA), calcium ionophore A23187, genistein, herbimycin A, and ER-27319 were prepared in dimethyl sulfoxide. They were diluted directly in buffer to give a final dimethyl sulfoxide concentration of Ͻ0.1% (vol͞vol). Controls were also incubated with an equal concentration of carrier solvent.
Preparation of Cells. RBL-2H3 cells were incubated overnight with DNP-specific IgE, 0. (14) . Cultures (2 ϫ 10 5 cells in 0.4 ml) were incubated in complete growth medium (minimal essential medium with Earle's salts and 15% heat-inactivated fetal calf serum) in 24-well culture plates. All cultures were washed twice in the desired buffer solutions before the final addition of 0.2 ml of fresh buffer and stimulants.
Rat peritoneal mast cells were obtained as described (15) . Cultured human mast cells were obtained by the method of Saito et al. (16) . Differentiation of the cultured human mast cells was monitored periodically with mouse antibody to tryptase and chymase. The human mast cells obtained were incubated overnight with human IgE, 10 g͞ml; and [
14 C]arachidonic acid, 1 Ci͞ml, to sensitize the cells. Cells (1 ϫ 10 6 in 0.5 ml) were stimulated with anti-human IgE antibody. Human B cells were partially purified from peripheral blood mononuclear cells of healthy adult donors by depletion of CD3 ϩ cells with a magnetic cell sorter (MACS, Miltenyi Biotec, Bergish Gladbach, Germany).
Measurements of Mediator Release. The accumulation of total [ 3 H]inositol phosphates was determined as previously described (17) . The release of radiolabeled arachidonic acid and 5-hydroxytryptamine was also determined as described (18) . The release of histamine was analyzed by enzyme immunoassay according to the manufacturer's instructions. Measurements of pLTs, prostaglandins, and TNF␣ were performed by enzyme immunoassays according to the manufacturer's instructions.
Analysis of Protein Tyrosine Phosphorylation and Western Blots. For tyrosine phosphorylation of total cellular proteins, cells were lysed by the addition of ice-cold lysis buffer [10 mM phosphate buffer (pH 7.5) containing 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 50 mM NaCl, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 50 g͞ml leupeptin, 10 units͞ml aprotinin, and 0.1% NaN 3 ]. Samples were centrifuged (14,000 ϫ g for 5 min at 4°C), mixed with SDS sample buffer [0.125 M Tris⅐HCl, pH 6.8͞4% (wt͞vol) SDS], boiled for 3 min, and resolved by SDS͞PAGE. For immunoprecipitation experiments with antibody to Syk, cells were lysed by ice-cold lysis buffer [20 mM Hepes buffer (pH 7.2) containing 1% Triton X-100, 10% (vol͞vol) glycerol, 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 50 g͞ml leupeptin, and 10 units͞ml aprotinin]. Cell lysates were incubated with the antibody at 4°C for 3 hr, and immunoprecipitated proteins were recovered. Immunoprecipitation of PLC-␥1 was performed exactly as described in a previous study (14) . Samples were resolved by SDS͞PAGE.
Immunoprecipitation of FcRI by means of cell-bound IgE was as described (19) with the exception that cells were incubated in the presence or absence of 30 or 60 M ER-27319 for 10 min at 37°C before stimulation with DNP-BSA. For immunoprecipitation of FcRI by the ␥ subunit, 32 g of an antibody (IgY fraction) raised in chickens to a synthetic peptide of the ␥ subunit of the FcRI and 100 g of rabbit anti-chicken IgY (Jackson Immunoresearch) were added for 1 hr at 4°C. Subsequently, protein A-Sepharose was added overnight. The recovered proteins were processed as described (19) . Western blots were as described (19) . Detection of resolved proteins with specific antibodies was as indicated in figure legends. Reactive proteins were visualized by ECL.
Measurement of Syk Tyrosine Phosphorylation Induced by Phosphorylated ITAMs or B Cell Stimulation. To test the effect of ER-27319 on the tyrosine phosphorylation of Syk induced by phosphorylated ITAMs, intact RBL-2H3 cells were homogenized in a Dounce homogenizer (100-150 strokes) in the presence of ice-cold lysis buffer [20 mM Tris⅐HCl (pH 7.5) containing 150 mM NaCl, 10 mM KCl, 0.5 mM EGTA, 2 mM dithiothreitol, 5 mM NaF, 1 mM Na 3 VO 4 , 50 g͞ml leupeptin, 10 units͞ml aprotinin, and 100 g͞ml soybean trypsin inhibitor]. Homogenates were centrifuged (100,500 ϫ g for 1 hr at 4°C) to collect soluble proteins. Tyrosine phosphorylation of Syk in the presence of ITAMs was done as described by Shiue et al. (20) .
We also tested the effect of ER-27319 on anti-IgM-induced Syk phosphorylation in human peripheral B cells. Human B cells were incubated with ER-27319 for 15 min at 37°C and then stimulated with anti-IgM ( chain, Organon Teknika-Cappel) for various times. Syk was subsequently immunoprecipitated, resolved by SDS͞PAGE, and analyzed by Western blotting.
Immune Complex in Vitro Kinase Assays. Syk was immunoprecipitated from cells that were treated or not with ER-27319 (30 or 100 M) or piceatannol (100 nM) for 10 min at 37°C followed by antigen activation for 3 or 10 min. The Syk immune complexes were incubated with 5 g of GST-HS1 in kinase buffer as described by Shiue et al. (20) for 5 min at 30°C with constant mixing. In some experiments ER-27319 or piceatannol was added in the kinase buffer to Syk immune complexes isolated from activated cells prior to addition of GST-HS1 and ATP. For Lyn immune-complex assays, Lyn was immunoprecipitated from lysates of activated cells treated with herbimycin A (10 M), genistein (300 M), or ER-27319 (30 or 100 M), and the activity was assayed as described (4) . All reactions were quenched by the addition of 5-fold concentrated SDS sample buffer and boiling.
RESULTS

ER-27319 Inhibits Antigen-Induced Cell Responses in RBL-
2H3 Cells. Table 1 shows that ER-27319 can effectively inhibit the antigen-induced secretion of 5-hydroxytryptamine, generation of inositol phosphates, release of arachidonic acid, and TNF␣ production in a concentration-dependent manner, achieving a half-maximal inhibition (IC 50 ) at a concentration of 10 M. Almost complete inhibition of all measured responses (Ͼ80%) was achieved at a concentration of ER-27319 of 30 M. Treatment of RBL-2H3 cells with ER-27319 before addition of the secretion-stimulating agents, A23187 and phorbol 12-myristate 13-acetate, did not significantly inhibit the secretion induced by these agents (Table 1) . At concentrations of up to 30 M only minimal inhibition of secretion was observed (13.8% Ϯ 2.7%). In contrast, the PKC inhibitor, Ro31-8425, selectively inhibited only the secretory response without affecting other responses to antigen (data not shown).
Collectively, the data demonstrate that ER-27319 is likely to mediate its inhibitory effect upstream of PKC, because it inhibits both hydrolysis of phosphatidyinositol and metabolism of arachi-donic acid. This promotes the idea that this compound may target an early step proximal to the activation of the FcRI Tables 1 and  2 , treatment of mast cells with ER-27319 inhibits both early and late events in mast cell responses.
Human mast cells were obtained by long-term (8-10 weeks) culture of umbilical cord blood mononuclear cells in the presence of stem cell factor (SCF), interleukin-6 (IL-6), and prostaglandin E 2 (PGE 2 ) (16). The cultured umbilical cord blood mononuclear cells were periodically analyzed for histamine content and tryptase-positive cells. After 8 weeks 90% of the cells were tryptase positive and had a histamine content of 498.9 Ϯ 110.6 ng per 10 5 cells (data not shown), values consistent with previous reports (16) . Treatment of the 8-to 10-week cultured human mast cells with human IgE followed by anti-human IgE stimulated histamine secretion (103.8 Ϯ 28.2 ng per 10 5 cells) and arachidonic acid release (8.21% Ϯ 0.91%). As shown in Table 2 Therefore we asked whether ER-27319 was Syk selective or whether it might also inhibit the tyrosine phosphorylation of the Syk-related ZAP-70 kinase found in Jurkat T cells. Fig. 1D shows that ER-27319 at concentrations of up to 100 M and preincubation times of up to 60 min did not inhibit the tyrosine phosphorylation of ZAP-70 in response to anti-CD3 stimulation of the Jurkat cells. Because PLC-␥1, a known target of Syk activity (21) , is found in both the RBL-2H3 cells and Jurkat T cells, we postulated that if ER-27319 is Syk selective the tyrosine phosphorylation of PLC-␥1 in Jurkat cells should not be affected by this drug. Following a 10-min stimulation of RBL-2H3 cells with antigen or of Jurkat T cells with antibody to CD3, tyrosine phosphorylation of PLC-␥1 was inhibited by ER-27319 only in the RBL-2H3 cells (Fig. 1E) .
Collectively, the results show that ER-27319 mediates its effect prior to activation of PLC-␥1. Since ER-27319 did not inhibit the ZAP-70-induced tyrosine phosphorylation of PLC-␥1 in Jurkat T cells, this suggests that the specific target of ER-27319 is Syk kinase. ER-27319 Inhibits Neither Lyn Kinase Activity nor the Phosphorylation of the IgE Receptor ␤ and ␥ Subunits. We examined whether ER-27319 inhibits Syk phosphorylation by inhibiting Lyn kinase activity, which is required for phosphorylation of the ␤ and ␥ subunits of FcRI and the subsequent binding and activation of Syk (10-13). As shown in Fig. 2A, phosphorylate PKC␦ (22) . In fact, we consistently saw a small enhancement in Lyn activity when cells were treated with ER-27319 (Fig. 2 A, lane 4) . In contrast, pretreatment of the cells with herbimycin or genistein effectively inhibited Lyn activity (Fig. 2 A, lanes 2 and 3) . Furthermore, the addition of ER-27319 (100 M) to Lyn immune complexes isolated from activated cells had no effect on Lyn activity (data not shown).
As shown in Fig. 2B (lanes 4 and 5) , immunoprecipitation of the FcRI, by means of cell surface-bound IgE, from cells treated or not with ER-27319, clearly demonstrated that tyrosine phosphorylation of the receptor subunits is also unaffected by this agent. Moreover, immunoprecipitation with an antibody to the FcRI ␥ subunit that does not react well with the phosphorylated species of this subunit (Fig. 2B, lanes 7 and 8) We also tested whether ER-27319 might inhibit the activation of Syk induced by the phosphorylated Ig␤ ITAM. Cytosolic lysates of RBL-2H3 cells, which contain most of the cellular Syk, were incubated with 50 M ATP and phosphorylated ITAMs. Fig. 3 shows the tyrosine phosphorylation of Syk in response to incubations with the phosphorylated ␥ subunit or Ig␤ ITAMs. ER-27319 inhibited the tyrosine phosphorylation of Syk induced by the phospho-␥ ITAM of the FcRI ␥ (Fig.  3A) but not the tyrosine phosphorylation of Syk induced by the phospho-Ig␤ ITAM (Fig. 3B) . In the presence of 10 M or 30 M ER-27319, Syk phosphorylation induced by the phospho-␥ ITAM of the FcRI ␥ was inhibited by 68% Ϯ 9.9% and 93% Ϯ 3.3%, respectively. However, concentrations of ER-27319 of up to 100 M had no effect on the Ig␤ ITAM-induced phosphorylation of Syk. These results suggest that ER-27319 selectively inhibits the tyrosine phosphorylation of Syk induced by the interaction of Syk with the ITAM of the FcRI ␥ subunit but not with the ITAM of Ig␤.
To further define the selectivity of ER-27319, human peripheral B cells were incubated in the presence or absence of ER-27319 and subsequently were stimulated with anti-IgM to induce tyrosine phosphorylation of Syk. Fig. 3C demonstrates that ER-27319 at 30 M, a concentration that effectively inhibited Syk phosphorylation and degranulation of mast cells, failed to inhibit the tyrosine phosphorylation of Syk in B cells. Concentrations of up to 100 M did not inhibit Syk phosphorylation in stimulated B cells. In addition, prolonged incubation of B cells (60 min) with ER-27319 did not inhibit Syk phosphorylation. In preliminary experiments, mast cell selectivity was further reinforced, since ER-27319 pretreatment of human platelets did not inhibit thrombin-induced platelet aggregation (data not shown).
These results suggest that ER-27319 specifically inhibits the interaction of Syk with the FcRI ␥ subunit ITAM. This would predict that ER-27319 would be effective prior to activation of Syk but not subsequent to its activation. We tested this possibility by in vitro immune-complex kinase assays that utilized an in vivo substrate of Syk, GST-HS1 (24) . Fig. 4 shows that pretreatment of RBL-2H3 cells with ER-27319 (30 M) results in the inhibition of both Syk phosphorylation and activity. In three experiments, an inhibition of 66.3% Ϯ 9.1% of the tyrosine phosphorylation of Syk was observed. Furthermore, Syk activity was inhibited by 68.7% Ϯ 11.3%. In comparison, Syk activity from cells treated with piceatannol was completely inhibited, as was the tyrosine phosphorylation. The addition of ER-27319 (30 M) directly to Syk immune complexes from activated cells inhibited neither the activity of Syk (Fig. 4, lane 6 ) nor its tyrosine phosphorylation. Concentrations of up to 100 M had no effect on the phosphorylation of Syk and its activity (data not shown). In contrast, piceatannol completely inhibited the the tyrosine phosphorylation and activity of Syk when added to Syk immune complexes derived from activated cells (Fig. 4, lane 7) . Collectively, these results show that ER-27319 selectively interferes with the activation of Syk, presumably by inhibiting its interaction with the FcRI ␥ subunit ITAM, thus inhibiting its activation. However unlike piceatannol, ER-27319 appears to have no effect on Syk once the kinase is active.
DISCUSSION
The critical role of Syk in FcRI-mediated mast cell and basophil responses has been clearly demonstrated by the overexpression of Syk constructs with dominant-negative phenotypes that abrogated the release of allergic mediators (25) . Therefore, the development of mast cell selective inhibitors of Syk may provide a reasonable approach toward therapeutic Because it targets Syk its use as a therapeutic agent in allergies is of interest, although it may be limited by its inhibition of B cell and platelet function. In this study we present evidence for another class of inhibitors, represented by the parental acridone-related compound ER-27319, that specifically inhibit the tyrosine phosphorylation of Syk initiated by engagement of the FcRI in rat and human mast cells. Our studies demonstrate that the inhibition of Syk tyrosine phosphorylation and activity by ER-27319 is mast cell selective and results in abrogation of degranulation, TNF␣ production, and related signaling events. The activity of Syk is required for tyrosine phosphorylation and activation of the downstream effector PLC-␥ (21). This results in the generation of inositol phosphates and diacylglycerol, leading to mobilization of intracellular Ca 2ϩ and activation of PKC (1), resulting in secretion (29) . The results of this study demonstrate that ER-27319 inhibits all of the aforementioned events we studied, consistent with the inhibition of Syk by this compound. The critical role of Syk in cell activation is not restricted to mast cells and basophils but is also important to B cell and platelet function (30, 31) . In B cells, Syk activity is induced by its association with the Ig␣͞Ig␤ ITAMs (23) . However, our results suggest that the induction of the tyrosine phosphorylation of Syk by the Ig␤ ITAM is not inhibited by ER-27319, while that induced by the ␥ subunit ITAM is effectively inhibited. Furthermore, ER-27319 had no effect on anti-IgM-induced Syk phosphorylation in human peripheral B cells. At the moment we have no clear explanation for the mechanistic differences in the preferential inhibition of mast cell Syk phosphorylation by ER-27319, although several possibilities exist. For example, ER-27319 may bind specifically to either the FcRI ␥ subunit ITAM or to a particular region of Syk and thus inhibit the ability of Syk to bind the ␥ subunit ITAM and be activated by autophosphorylation or transphosphorylation. Regardless, our results clearly demonstrate that ER-27319 inhibits the activation of Syk with no effect on activated Syk. This suggests that the specificity of this drug is for the process of Syk activation. Our results in human peripheral B cells and preliminary studies on platlets show mast cell selectivity and promote the therapeutic potential of ER-27319 in allergies.
Further experiments are required to determine the site of ER-27319 binding and the stereochemical changes, if any, induced by the binding of this agent to Syk or to the ␥ subunit ITAM. However, preliminary experiments using biosensor technology show that ER-27319 inhibits the interaction of Syk with the FcRI ␥ subunit phospho-ITAM but only minimally affects its interaction with the Ig␤ phospho-ITAM (data not shown). Furthermore, additional experiments suggest that ER-27319 does not bind directly to the FcRI ␥ subunit phospho-ITAM.
